August 7, 2025 — Leads & Copy — eXoZymes Inc. (NASDAQ:EXOZ) will host a webinar on Tuesday, August 12, 2025, at 5:00 PM Eastern Time to discuss its results for the second quarter of 2025. The company is a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals.
Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, and anticipated milestones, as well as host a question-and-answer session.
Investors can pre-register for the webinar HERE. The live webinar can also be accessed on the day of the event through eXoZymes’ investor relations website.
Founded in 2019, eXoZymes has developed a biomanufacturing platform that offers the tools and insights to design, engineer, control, and optimize nature’s own natural processes to produce chemical compounds. This enables the company’s partners to upgrade traditional petrochemical production methods with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes.
Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor without using living cells. They can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels. By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.
While the company, eXoZymes Inc., has introduced “exozymes” as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.
Lasse Görlitz, VP of Communications, can be reached at (858) 319-7135 or press@exozymes.com.
